Mylan launches generic acne treatment
CANONSBURG – Mylan N.V. announced Monday the U.S. launch of Doxycycline Hyclate Delayed-Release tablets in a 200-milligram dose.
The product is a generic version of Mayne’s Doryx, a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne.
Mylan received final approval from the U.S. Food and Drug Administration, and was awarded 180 days of marketing exclusivity for the product.
The medicine had U.S. sales of about $181.8 million for the 12 months ending March 31, 2016, according to IMS Health.